Glycocalyx

Travere Therapeutics Announces Presentations of Abstracts at the 59th ERA Congress

Retrieved on: 
Tuesday, May 17, 2022
Disease, Medicine, Food, U.S. Securities and Exchange Commission, Losartan, Form 10-K, EGFR, Podocyte, ERA, Glomerular basement membrane, NDA, Private Securities Litigation Reform Act, Heart Protection Study, II, CMA, Therapy, COVID-19, Patent, SAN, Kidney, GLOBE, Chronic kidney disease, Company, Albuminuria, Focal segmental glomerulosclerosis, FSGS, Priority review, Patient, FDA, Immunoglobulin A, Ongoing reliability test, Congress, Irbesartan, ETAR, Security (finance), Risk, PROTECT, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NASDAQ, Treatment, ARB, Form 10-Q, Caregiver, Life, Safety, Glomerulosclerosis, Development, Pharmaceutical industry, Proteinuria, IgA nephropathy, Glycocalyx

The Company and its collaborators will also present nonclinical data examining the renal protective effects of sparsentan compared to controls.

Key Points: 
  • The Company and its collaborators will also present nonclinical data examining the renal protective effects of sparsentan compared to controls.
  • ERA is being held live in Paris, France, and virtually May 19-22, 2022.
  • In August 2021, the Company announced the PROTECT Study met its pre-specified interim primary efficacy endpoint with statistical significance.
  • The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Calroy Health Sciences Awarded U.S. Patent for Vulnerable Plaque Stabilization and Regression

Retrieved on: 
Thursday, November 18, 2021
Science, Cardiology, Biotechnology, Research, Pharmaceutical, Alternative Medicine, General Health, Health, Patent, Health, CEO, Research, Â, Permeability, Glycocalyx, Endothelium, Outline of health sciences, Pharmaceutical industry, Dietary supplement, Arterosil®, Calroy Health Sciences, ARTEROSIL®, CALROY HEALTH SCIENCES

The patent is a critical milestone as we establish the exceptional clinical value of Arterosil, said Ed Hoyt, President and CEO of Calroy Health Sciences.

Key Points: 
  • The patent is a critical milestone as we establish the exceptional clinical value of Arterosil, said Ed Hoyt, President and CEO of Calroy Health Sciences.
  • Calroy is committed to developing safe and effective products through robust scientific research, said Chen Chen, Ph.D., Chief Scientific Officer of Calroy Health Sciences.
  • The method by which Arterosil helps to stabilize and regress vulnerable plaque is covered under U.S. Patent 11,135,238.
  • Calroy Health Sciences is a company dedicated to science-based innovations that transform human health with natural solutions.

The NOSTRADAMUS Study: Microvascular Dysfunction in Sepsis

Retrieved on: 
Monday, April 19, 2021
Branches of biology, Biology, Cell biology, Glycobiology, Glycocalyx, Polymers, Polysaccharides, Endothelium, Microangiopathy

The study, titled "Identification of novel sublingual parameters to analyze and diagnose microvascular dysfunction in sepsis: the NOSTRADAMUS study" was published in Critical Care.

Key Points: 
  • The study, titled "Identification of novel sublingual parameters to analyze and diagnose microvascular dysfunction in sepsis: the NOSTRADAMUS study" was published in Critical Care.
  • "For several years, GlycoCheck has been used globally in groundbreaking research to understand the complex nature of the endothelial glycocalyx.
  • "\nThe study concludes that new important diameter-specific quantification and differentiated analysis of RBC kinetics is a key to understand microvascular dysfunction in sepsis.
  • MVHSdynamic, which has a broad bandwidth to detect micro-vascular (dys-) function, might serve as a valuable tool to detect microvascular impairment in critically ill patients.\nGlycoCheck analyzes glycocalyx, endothelium, and capillary function.

Clarkson University Physics Professor Awarded National Science Foundation CAREER Grant for More Than $500,000

Retrieved on: 
Monday, December 16, 2019
Branches of biology, Cell biology, Glycobiology, Glycocalyx, Polymers, Polysaccharides, Biology, Clarkson University, Clarkson, Endothelium, Scrimgeour

Potsdam, NY, Dec. 16, 2019 (GLOBE NEWSWIRE) -- Clarkson University Assistant Professor of Physics Jan Scrimgeour was awarded a CAREER grant from the National Science Foundation (NSF) for $541,591.

Key Points: 
  • Potsdam, NY, Dec. 16, 2019 (GLOBE NEWSWIRE) -- Clarkson University Assistant Professor of Physics Jan Scrimgeour was awarded a CAREER grant from the National Science Foundation (NSF) for $541,591.
  • Scrimgeour was awarded the grant for use on his project titled CAREER: Understanding the Structure and Function of the Endothelial Glycocalyx through Single Molecule Visualization.
  • The blood vessel wall is a unique living interface between flowing fluid and the tissues of our bodies.
  • The grant will fund one Clarkson graduate student for five years and will provide research experiences for undergraduate students, giving them hands-on experience in the lab full-time.